A Research Study Investigating Semaglutide in People With Early
Alzheimer's Disease (EVOKE)
This study is done to find out whether semaglutide has a positive effect on early Alzheimer's disease.
Participants will either get semaglutide or placebo - which treatment participants get is decided by an equal chance.
The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor.
Participants must have a study partner, who is willing to take part in the study.
|type of project||clinical studies|
|status||ongoing - recruiting phase|
|start of project||2021|
|end of project||2024|
|responsible person||Felbecker, Ansgar|